Neurocrine Biosciences
- Market cap
- 14.58B
- P/E (TTM)i
- 20.98
- P/Bi
- 3.95
- EPSi
- 4.67
- Div yieldi
- 0.00%
- 52W posi
- 33%
Anonymous reader poll. Unscientific, not investment advice.
Neurocrine Biosciences ended the session at 143.47, down 1.40%. That leaves the company valued at approximately 14.58B, the #1162 most valuable US-listed company we track. The trailing P/E of 20.81 is 79% below its five-year average of 98.71. The 24 analysts covering the stock are, on balance, at Buy, targeting an average of 209.96 (+46%). The shares sit 33% of the way up their 52-week range of 122.14 to 186.12.
✦ StockVane Quant Insights how this is computed
- Below its 200-day average or in the bottom third on momentum — the strategy is out of it.
- Signal has read SELL for 2 weeks.
- Recent price momentum is -7.2% on average (3-month/1-year).
- Main-fund capital flow has been a net outflow over the last 45 sessions.
- Short interest has fallen to 4.9% of float.
- Analyst tilt is Buy.
- Price is below its 20-day average and below its 60-day average.
- The 20-day average is below the 60-day average, a short-term downtrend.
Computed by a StockVane algorithm from historical price, valuation and analyst data - not a person, not a forecast guarantee, and not investment advice.
Factor grades
Ranked against 977 U.S. stocks StockVane covers.
Valuation B
How expensive the stock is versus earnings, sales and its own 5-year history.
| P/E (TTM) | 21.1x | Better than 44% |
| Forward P/E | 16.5x | Better than 54% |
| Price / Sales | 4.3x | Better than 33% |
| P/E vs own 5-yr range | 6th pctl | Better than 89% |
Growth A
How fast revenue, profit and free cash flow are compounding.
| Revenue CAGR (3Y) | 24.3% | Better than 88% |
| Net income CAGR (3Y) | 45.8% | Better than 89% |
| Free cash flow CAGR (3Y) | 32.4% | Better than 79% |
Profitability A-
How much profit the business keeps from each dollar of sales and capital.
| Gross margin | 98.2% | Better than 100% |
| Operating margin | 22.3% | Better than 70% |
| Net margin | 16.7% | Better than 67% |
| Return on equity | 16.4% | Better than 59% |
| Return on invested capital | 12.4% | Better than 65% |
Momentum C
Recent price strength, skipping the latest month to avoid short-term noise.
| 3-month return | -18.8% | Better than 12% |
| 6-month return | 10.2% | Better than 58% |
| 12-month return (ex latest month) | 11.6% | Better than 46% |
| Distance below 52-week high | 22.5% | Better than 42% |
Financial Health A-
Balance-sheet strength: leverage, liquidity and interest coverage.
| Current ratio | 3.4x | Better than 86% |
| Debt to assets | 9.0% | Better than 79% |
| Interest coverage | 4.8x | Better than 41% |
| Free cash flow / net income | 156.4% | Better than 74% |
Analyst View A-
What the Street thinks: share of Buy ratings and upside to the average target.
| Analysts rating Buy | 87.5% | Better than 69% |
| Upside to average target | 45.6% | Better than 80% |
Grades are relative rankings, not forecasts: A+ is the top 5% of the covered stocks on a factor, F the bottom 3%. Valuation is not adjusted for sector, so capital-light software tends to grade lower there than utilities. Recomputed every 6 hours from our market data. Not investment advice, and not tailored to your financial situation, goals, or risk tolerance.
Price chart
Performance
Key statistics
Price & volume
- Prev close
- 145.51
- Open
- 145.33
- Day range
- 143.21 - 145.88
- Avg price
- 144.16
- Volume
- 1.14M
- Turnover
- 164.88M
- Turnover ratei
- 1.14%
- Volume ratioi
- 0.58
- Amplitudei
- 1.84%
- 52-week rangei
- 122.14 - 186.12
Valuation
- P/Ei
- 30.72
- P/E (TTM)i
- 20.98
- P/Bi
- 3.95
- EPSi
- 4.67
- Book value / shi
- 36.34
- Net profit
- 474.70M
- Net assets
- 3.69B
Share structure
- Market cap
- 14.58B
- Float capi
- 14.40B
- Shares out
- 101.65M
- Float sharesi
- 100.37M
Dividend & listing
- Div yield (TTM)i
- 0.00%
- Dividend (TTM)
- 0.00
- Listing date
- 1970-01-01
22.9% below the 52-week high
Trading activity
Net capital flow main funds, last 45 sessions
-73.88M net over the window
Short interest
- Shares short
- 4.96M
- % of floati
- 4.88%
- Days to coveri
- 5.37
- As of
- 2026-09-15
Frequently asked questions
What is the current stock price of Neurocrine Biosciences (NBIX)?
Neurocrine Biosciences last traded at 143.47. The quote on this page refreshes every few seconds while US markets are open.
What is Neurocrine Biosciences's market cap?
About 14.58B.
What is the P/E ratio of Neurocrine Biosciences?
The trailing twelve-month P/E is 20.98, below its own 5-year average of 98.71 — toward the bottom of its historical range (6.23% percentile). See the Valuation tab for the full history.
Does Neurocrine Biosciences pay a dividend?
Neurocrine Biosciences does not currently pay a regular dividend.
Is Neurocrine Biosciences a buy according to analysts?
The consensus of 24 analysts is a Buy rating, with an average 12-month price target of 209.96, which implies 46.3% upside from the current price. This is not investment advice.
What is Neurocrine Biosciences's StockVane Quant Rating?
The StockVane Momentum strategy currently rates Neurocrine Biosciences a D (Sell). Below its 200-day average or in the bottom third on momentum — the strategy is out of it. Not investment advice.
Quote time 2026-10-08 07:09:44 · For reference only, not investment advice and not tailored to your situation.